Vitiligo Treatment by Targeting TYK2 Mediated Responses

PHASE2RecruitingINTERVENTIONAL
Enrollment

128

Participants

Timeline

Start Date

May 5, 2024

Primary Completion Date

May 5, 2026

Study Completion Date

November 5, 2026

Conditions
Vitiligo, Generalized
Interventions
DRUG

Deucravacitinib

Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.

OTHER

Volunteer without treatment

Throughout the study, there will be a total of six visits conducted: selection, inclusion, Week 12, Week 24, Week 36, and Week 48. In patients who volunteer, a skin biopsy will be performed on both the lesional and peri-lesional areas at baseline, Week 12 and Week 36. Serum and plasma samples will be collected at the screening visit, Week 12, Week 24, Week 36, and Week 48.

Trial Locations (5)

33000

RECRUITING

CHU de Bordeaux, Bordeaux

06200

RECRUITING

CHU de Nice - Hôpital de l'Archet, Nice

Unknown

RECRUITING

APHP, Henri Mondor, Paris

RECRUITING

CHU de Lille, Lille

RECRUITING

HCL, Lyon

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER